RecruitingNCT07144332

This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Order to Evaluate the Need of Adjuvant Uric Acid Lowering Therapy

Assessment of the Efficacy of Hemodialysis on Uric Acid Clearance at End Stage Kidney Disease in Sohag University Hospital

Sponsor

Sohag University

Enrollment

100 participants

Start Date

Jul 13, 2025

Study Type

OBSERVATIONAL

Conditions

Hyperuricemia Hemodialysis

Summary

Background: Uricemia dramatically rises with the stage of chronic kidney disease (CKD) and correlates with its mortality. Hemodialysis (HD) being the most used treatment at the end stage kidney disease in Sohag governorate , we sought to evaluate its efficacy on the clearance of uric acid (UAc) when used alone and twice per week. Methods: A cross-sectional study of all consenting patients with CKD stage 5 recruited at random during hemodialysis sessions at hemodialysis unit in Sohag university hospital from July to December 2025. We collected socio-demographic data, relevant clinical information, hemodialysis related variables, and measured serum uric acid (SUA) levels before and after the dialysis to assess the uric acid clearance. A clearance between 65 and 80% and above 80% was considered as low and good efficacy of hemodialysis respectively

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how well regular hemodialysis (kidney dialysis) removes uric acid from the blood in patients on long-term dialysis, and whether those patients need additional uric acid-lowering medications. High uric acid can cause gout and other health problems. **You may be eligible if...** - You are 18 years or older - You have been on regular hemodialysis (kidney dialysis) for at least 3 consecutive months - You receive 2 to 3 dialysis sessions per week - You have agreed to participate **You may NOT be eligible if...** - You are under 18 years old - You have been on dialysis for less than 3 months - You are already taking uric acid-lowering medications (such as allopurinol or febuxostat) - You receive less than 4 hours per dialysis session or require emergency dialysis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.